We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
- Authors
Kinoshita, Y.; Kuratsukuri, K.; Newman, N.; Rovito Jr., P. M.; Kaumaya, P. T. P.; Wang, C. Y.; Haas, G. P.
- Abstract
Prostate-specific membrane antigen (PSMA) is a target for immunotherapy of prostate cancer. It has been shown that antibodies against PSMA inhibited the in vivo growth of LNCaP tumor. In the present study, monoclonal antibodies against four epitopes in PSMA were raised. MAb 24.4E6 (IgG1), specific for the epitope (residues 638–657) in PSMA, significantly reduced the growth rate of established LNCaP tumor in SCID mice. Mouse IgG was detected in the tumor of mice treated with 24.4E6, but not with an unrelated MAb. These results suggest that this epitope may be the main target in PSMA for antibody therapy of prostate cancer.Prostate Cancer and Prostatic Diseases (2005) 8, 359–363. doi:10.1038/sj.pcan.4500835; published online 20 September 2005
- Subjects
PROSTATE cancer; IMMUNOGLOBULINS; PROSTATE-specific membrane antigen; EPITOPES; CARBOXYPEPTIDASES
- Publication
Prostate Cancer & Prostatic Diseases, 2005, Vol 8, Issue 4, p359
- ISSN
1365-7852
- Publication type
Article
- DOI
10.1038/sj.pcan.4500835